Novartis mulls appeal against NICE no for Jakavi
This article was originally published in Scrip
Executive Summary
Novartis is deciding on its next steps, which could include an appeal, after NICE, the health technology appraisal institute for England and Wales, maintained a negative recommendation on the company's JAK inhibitor, Jakavi (ruxolitinib), in final draft guidance published 26 April.